googleads

Global Pharmerging Markets 2017-2021

  • Published: Jan 2017
  • Pages: 116
  • SKU: IRTNTR11577
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version!

Pharmerging market outlook

Technavio’s market research analyst predicts the global pharmerging markets to grow steadily at a CAGR of around 13% by 2021. One of the primary drivers for this market is the increasing focus toward biosimilar in potential areas. As most of the patents for originator biologics have expired, the vendors are focusing on the development of duplicate copies of biologics, called biosimilars. These biosimilars provide the same efficacy as that of parent molecule but at a cheaper cost.

The availability of cheap manufacturing resources such as land and labor has made the pharmerging market an important option for the development of these biosimilars. For instance, in 2014 trastuzumab, (a biosimilar of CANMab), which is indicated for the treatment of metastatic breast cancer was launched in India. Moreover, the on-going strong market growth in therapeutic areas will contribute further to higher penetration of the pharmerging markets over the next few years. 

Pharmerging market trends

Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

  • Market overview

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Highlights

PART 05: Global pharmaceutical market

  • Market size and forecast

PART 06: Road to pharmerging markets

PART 07: Pharmerging markets

PART 08: Market landscape

  • Medicine spending in emerging economies
  • Five forces analysis

PART 09: Market segmentation  by geography

PART 10: Market overview of tier I countries

  • China

PART 11: Market overview of tier II countries

  • Brazil
  • Russia
  • India

PART 12: Market overview of tier III countries

  • Market size and forecast

PART 13: Market drivers

  • Limitations in developed economies fuels demand in emerging economies
  • Increasing focus toward biosimilar in potential areas
  • Expansion initiatives of vendors

PART 14: Impact of drivers

PART 15: Market challenges

  • IP protection issues
  • Socio-political issues in cross geography transactions
  • Stringent price control and generic-centric usage lead to value erosion

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Potential of new countries in emerging markets
  • Positive outlook toward adoption of targeted therapies
  • Evolving stakeholder landscape to change market dynamics

PART 18: Vendor landscape

  • Competitive scenario

PART 19: Key vendor analysis

  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • Novartis
  • Other prominent vendors

PART 20: Appendix

  • List of Abbreviations

PART 21: Explore Technavio

Tags: medical technology, pharma sector, medical devices, medical companies, healthcare industry outlook, medical devices industry overview,

Safe and Secure SSL Encrypted
Technavio
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

*For Enterprise license, go to checkout page

*Avail subscription at 50% off, with report purchase - limited to a week

  • 2500 USD


[5 reports/month/user]

close
  • Basic Plan [5000 USD/Year]:

    Single User
    Download 5 Reports/Month
    View 100 Reports/Month
    Add upto 3 Users at 625 USD/user

  • Teams Plan [7500 USD/Year]:

    5 User
    Download 5 Reports/Month/User
    View 100 Reports/Month/User
    Add upto 30 Users at 500 USD/user

*You can upgrade to Teams plan at Subscription page

  • 5000 USD

Quick BuyTechnavio
View Free Data Sample
VIEW FREE SAMPLE PDF

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights